Medecine assisted | BIOTAI bispecific neutralizing antibody drug BAT2022 was approved clinically.

저자：medicilon   업로드：2022-07-04  조회수：

On June 10, 2022, Bio-Thera Solutions, Ltd. （Bio-Thera） announced that BAT2022 for injection has obtained a clinical trial approval.  BAT2022 for injection is a bispecific neutralizing antibody independently developed by Bio-Thera, which is intended to be used for the treatment of new coronary pneumonia caused by the infection of the COVID19 and its mutants.

Shanghai Medicilon Inc. was honored to participate in the R&D project of Bio-Thera BAT202 for injection, providing a safety evaluation test that complied with the GLP specification and assisting the project successfully obtain clinical approval with compliant, efficient and high-quality services.

Bio-Thera is committed to developing a new generation of innovative drugs and biosimilars for the treatment of tumors, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life or health.  As a leader in the research and development of next-generation antibody drugs, Bio-Thera has promoted a number of drug candidates into later-stage of clinical trials.

Since the founding of our company in 2004, Medicilon （Stock Code: 688202.SH） has grown into one of the professional?drug discovery contract research organizations （CRO）？in China.  Over the years, Medicilon keeps improving their services in?biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of 2021, Medicilon has provided new drug R&D services to more than 1,460 clients around the world, and participated in the R&D of 221 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.

이전：Medicilon and Xiling Lab formed a strategic partnership

다음에：Medicilon Appoints Dr. Christopher Stewart, DABT as Senior Scientific Advisor